ADRA2A Antibody

What is ADRA2A and why is it important for research?

ADRA2A (adrenoceptor alpha 2A) is a G-protein coupled receptor with significant roles in cellular signaling pathways. In humans, the canonical ADRA2A protein consists of 465 amino acid residues with a molecular mass of 50.6 kDa . It primarily localizes to the cell membrane and is involved in cytoskeleton organization and GPCR signaling pathways . ADRA2A undergoes post-translational modifications, including glycosylation, which affect its function and detection .

The protein is significant for research across multiple disciplines due to its diverse functional roles. In neuroscience and cardiovascular research, it functions as an adrenergic receptor mediating various physiological responses. Cancer biology investigations have revealed its potential role as a tumor suppressor, particularly in pancreatic ductal adenocarcinoma (PDAC), where its expression correlates with cancer subtypes and patient outcomes . In cellular biology, ADRA2A serves as a marker for specific cell types, including Ureter Vascular Smooth Muscle Cells and Bladder Vascular Smooth Muscle Cells .

ADRA2A has several synonyms in the literature, including ADRA2R, ADRAR, ALPHA2AAR, ZNF32, and alpha-2A adrenergic receptor . Orthologs have been identified across numerous species including mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken, making it valuable for comparative studies .

What are the common applications of ADRA2A antibodies in research?

ADRA2A antibodies are versatile tools employed across multiple research applications:

The choice of application depends on the specific research question. For protein expression quantification, Western blotting provides semi-quantitative data, while flow cytometry offers single-cell resolution. For spatial information about protein distribution, immunohistochemistry or immunofluorescence are optimal approaches. Many commercially available ADRA2A antibodies are validated for multiple applications, providing flexibility in experimental design .

Research protocols typically require optimization for each application. For example, immunoblotting protocols from published research utilize RIPA buffer with protease inhibitors for cell lysis, followed by separation on 4-15% polyacrylamide gels under reducing conditions .

How should researchers validate the specificity of ADRA2A antibodies?

Antibody validation is critical for ensuring reliable and reproducible research outcomes. For ADRA2A antibodies, several complementary validation approaches are recommended:

A robust validation protocol based on published research might include:

• Establishing ADRA2A-overexpressing cell lines using lentiviral transduction

• Confirming overexpression by qPCR using validated probes

• Performing Western blot analysis with the antibody under investigation

• Including appropriate positive controls (overexpression) and negative controls (empty vector)

• For flow cytometry applications, comparing signal between labeled samples, isotype controls, and unlabeled controls

The flow cytometry validation protocol described in research literature includes careful comparison between samples stained with anti-ADRA2A antibody (test sample), isotype control antibody, and unstained samples, allowing clear discrimination between specific and non-specific signals .

What species reactivity can be expected from ADRA2A antibodies?

The species reactivity of ADRA2A antibodies varies by product, but many commercially available antibodies demonstrate cross-reactivity with multiple species due to the conservation of protein sequence across vertebrates:

When selecting an ADRA2A antibody for cross-species applications, researchers should:

• Verify the epitope sequence conservation across target species

• Test antibody specificity in each species of interest

• Consider using antibodies raised against conserved regions when working with multiple species

• Validate reactivity empirically in each new species application

Many commercially available antibodies are specifically validated for human, mouse, and rat samples, facilitating comparative studies across these commonly used research models . This cross-reactivity is particularly valuable for translational research bridging findings between animal models and human applications.

What are the optimal conditions for using ADRA2A antibodies in flow cytometry?

Flow cytometry enables quantitative analysis of ADRA2A expression at the single-cell level. Based on published protocols, successful ADRA2A antibody use in flow cytometry requires optimization of several parameters:

A methodological approach based on published research includes:

• Fix cells with 4% paraformaldehyde

• Block with 10% normal serum matching the host species of secondary antibody

• Incubate with primary anti-ADRA2A antibody (1 μg per 1×10^6 cells)

• Wash thoroughly to remove unbound primary antibody

• Incubate with fluorophore-conjugated secondary antibody (5-10 μg per 1×10^6 cells)

• Include all necessary controls: isotype control, unstained cells, secondary-only control

• Analyze using appropriate instrument settings with compensation if performing multi-color analysis

For directly conjugated ADRA2A antibodies (e.g., Alexa Fluor 647-conjugated), the protocol is simplified by eliminating the secondary antibody step, potentially reducing background and variability .

How does ADRA2A expression correlate with cancer phenotypes?

Recent research has revealed important correlations between ADRA2A expression and cancer phenotypes, particularly in pancreatic ductal adenocarcinoma (PDAC):

The clinical significance of ADRA2A expression in PDAC includes:

• Correlation with pathological features: Reduced ADRA2A expression is associated with higher frequency of lymph node metastasis, higher pathological grade, and advanced disease stage .

• Survival impact: Lower ADRA2A expression correlates with decreased patient survival .

• Functional effects: ADRA2A appears to play a tumor-suppressive role:

  • ADRA2A transgene expression inhibits PDAC cell invasion

  • ADRA2A agonists show inhibitory effects on PDAC cell invasion

• Molecular mechanisms: ADRA2A influences key cellular pathways:

  • Upregulated ADRA2A downregulates the MYC signaling pathway

  • ADRA2A promotes the classical/progenitor gene expression profile

• Metabolic impact: ADRA2A modulates cancer metabolism:

  • Elevated ADRA2A levels are associated with suppressed amino acid metabolism

  • Elevated ADRA2A levels are associated with suppressed carnitine/acylcarnitine metabolism

  • These metabolic changes resemble the classical/progenitor PDAC subtype profile

These findings suggest ADRA2A may serve as both a diagnostic marker and potential therapeutic target in PDAC, with particular relevance for distinguishing between molecular subtypes with different clinical behaviors .

What methodological approaches are recommended for ADRA2A detection in tissue samples?

Detecting ADRA2A in tissue samples requires careful methodological consideration to ensure specific and sensitive detection:

The scoring system described in research protocols provides a comprehensive approach to quantification:

• Intensity scoring (0-3):

  • 0: Negative (no staining)

  • 1: Weak staining

  • 2: Moderate staining

  • 3: Strong staining

• Prevalence scoring (0-4):

  • 0: <10% positive cells

  • 1: 10-30% positive cells

  • 2: >30-50% positive cells

  • 3: >50-80% positive cells

  • 4: >80% positive cells

• Final IHC score: Calculated by multiplying intensity and prevalence scores (range: 0-12)

This semi-quantitative approach enables statistical comparison between different samples or experimental conditions, providing valuable data on ADRA2A expression patterns in various tissue contexts.

What controls are essential when using ADRA2A antibodies?

Comprehensive controls are essential for ensuring reliable and interpretable results when using ADRA2A antibodies:

Based on published flow cytometry protocols, a comprehensive control strategy includes:

• Sample stained with anti-ADRA2A antibody and secondary antibody (test sample)

• Sample stained with isotype control antibody and secondary antibody (isotype control)

• Unlabelled sample without primary or secondary antibody (blank control)

• Sample stained with secondary antibody only (secondary-only control)

For genetic validation, lentiviral systems using ADRA2A construct (e.g., EX-Z5688-Lv103) and empty vector control (e.g., EX-NEG-Lv103) provide an excellent approach for creating controlled expression systems to validate antibody specificity .

How can ADRA2A antibodies be used to study metabolic phenotypes in cancer?

Recent research has identified important connections between ADRA2A expression and metabolic phenotypes in cancer, particularly pancreatic ductal adenocarcinoma (PDAC). Researchers can leverage ADRA2A antibodies to investigate these metabolic relationships through several approaches:

Published research demonstrates that ADRA2A influences key metabolic pathways in PDAC:

• Amino Acid Metabolism: Elevated ADRA2A expression is associated with suppressed amino acid metabolism, a characteristic feature of the classical/progenitor PDAC subtype .

• Lipid Metabolism: ADRA2A upregulation correlates with reduced carnitine/acylcarnitine metabolism, suggesting altered fatty acid oxidation .

• Cancer Subtype-Specific Metabolism: ADRA2A expression helps define metabolic features that distinguish between classical/progenitor and basal-like/squamous PDAC subtypes .

A comprehensive experimental approach would include:

• Stratify samples based on ADRA2A expression levels using validated antibodies

• Perform untargeted metabolomic profiling using standardized platforms

• Integrate metabolomic data with ADRA2A expression data

• Validate findings using genetic manipulation of ADRA2A expression

• Analyze pathway-level metabolic changes using tools like MetaboAnalyst 5.0

This integrated approach allows researchers to establish mechanistic links between ADRA2A expression and metabolic reprogramming in cancer.

What are the considerations for multiplexing ADRA2A with other markers?

Multiplexing allows simultaneous detection of ADRA2A with other markers to gain context about cell types, signaling states, or disease processes:

When designing multiplexed experiments with ADRA2A antibodies, researchers should consider:

• Antibody compatibility:

  • Host species combinations to avoid cross-reactivity

  • Primary antibody pairs from different species (e.g., rabbit anti-ADRA2A with mouse antibodies against other targets)

  • Secondary antibody selection to prevent cross-reactivity

• Signal separation:

  • Choose fluorophores with minimal spectral overlap for immunofluorescence

  • Implement appropriate compensation controls for flow cytometry

  • Consider brightness matching for targets with different expression levels

• Marker selection for PDAC research:

  • Classical/progenitor markers to correlate with ADRA2A high expression

  • Basal-like/squamous markers to correlate with ADRA2A low expression

  • MYC pathway components (as ADRA2A appears to downregulate this pathway)

  • Metabolic markers related to amino acid and carnitine/acylcarnitine metabolism

The flow cytometry protocol described in research literature could be adapted for multiplexing by incorporating additional primary antibodies and appropriately conjugated secondary antibodies with distinct fluorophores .

How can researchers optimize Western blot protocols for ADRA2A detection?

Western blotting is a fundamental technique for detecting and semi-quantifying ADRA2A protein. Based on published protocols, the following optimized approach is recommended:

Troubleshooting considerations for ADRA2A Western blotting include:

• Multiple bands: ADRA2A may appear as multiple bands due to post-translational modifications, particularly glycosylation . Consider deglycosylation treatments to confirm specificity.

• Low signal: Given ADRA2A's potential low abundance in some tissues, consider:

  • Extended exposure times

  • Enhanced chemiluminescence (ECL) detection systems

  • Signal amplification systems

• High background: If experiencing high background, optimize:

  • Blocking conditions (time, buffer composition)

  • Washing stringency (duration, buffer formulation)

  • Antibody dilutions

• Quantification approach: For semi-quantitative analysis:

  • Use β-Actin as loading control (1:2000 dilution)

  • Employ digital image analysis software for densitometry

  • Normalize ADRA2A signal to loading control

Following these optimized protocols should result in specific detection of ADRA2A with minimal background interference.

What are the advanced approaches for studying ADRA2A in cellular signaling pathways?

ADRA2A, as a G-protein coupled receptor, participates in complex signaling networks. Advanced approaches for investigating these pathways include:

Published research demonstrates that ADRA2A influences several key signaling pathways:

• MYC Signaling: Upregulated ADRA2A has been shown to downregulate the MYC signaling pathway in PDAC cells .

• Classical/Progenitor Gene Expression: ADRA2A upregulation promotes gene expression profiles characteristic of the classical/progenitor PDAC subtype .

• Metabolic Pathway Regulation: ADRA2A expression affects amino acid metabolism and carnitine/acylcarnitine metabolism pathways .

A comprehensive experimental approach might include:

• Baseline analysis of ADRA2A expression and localization

• Genetic manipulation using lentiviral ADRA2A expression systems

• RNA sequencing to identify transcriptional changes (as done in CFPAC-1 cells in published protocols)

• Integration of transcriptomic and metabolomic data to build comprehensive signaling models

• Validation of key findings using pharmacological approaches (agonists/antagonists)

This multi-modal approach allows researchers to develop a comprehensive understanding of ADRA2A's role in cellular signaling networks across different biological contexts.